Current Oncology Reports

, Volume 6, Issue 1, pp 1–2 | Cite as

Is it time for oncologists to modify their laissez-faire attitude toward alternative/ complementary ‘drug therapy’?

  • Maurie Markman
Editor’s Commentary


  1. 1.
    Burstein HJ, Gelber S, Guadagnoli E, et al.: Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 1999, 340:1733–1739.PubMedCrossRefGoogle Scholar
  2. 2.
    Lippert MC, McClain R, Boyd JC, et al.: Alternative medicine use in patients with localized prostate carcinoma treated with curative intent. Cancer 1999, 86:2642–2648.PubMedCrossRefGoogle Scholar
  3. 3.
    Risberg T, Lund E, Wist E, et al.: Cancer patients use of nonproven therapy: a 5-year follow-up study. J Clin Oncol 1998, 16:6–12.PubMedGoogle Scholar
  4. 4.
    Ernst E, Cassileth BR: The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 1998, 83:777–782.PubMedCrossRefGoogle Scholar
  5. 5.
    Fernandez CV, Stutzer CA, MacWilliam L, et al.: Alternative and complementary therapy use in pediatric oncology patients in British Columbia: prevalence and reasons for use and nonuse. J Clin Oncol 1998, 16:1279–1286.PubMedGoogle Scholar
  6. 6.
    Metz JM, Jones H, Devine P, et al.: Cancer patients use unconventional medical therapies far more frequently than standard history and physical examination suggest. Cancer J 2001, 7:149–154.PubMedGoogle Scholar
  7. 7.
    Richardson MA, Sanders T, Palmer JL, et al.: Complementary/ alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000, 18:2505–2514.PubMedGoogle Scholar
  8. 8.
    Boon H, Stewart M, Kennard MA, et al.: Use of complementary/ alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol 2000, 18:2515–2521.PubMedGoogle Scholar
  9. 9.
    Ruschitzka F, Meier PJ, Turina M, et al.: Acute heart transplant rejection due to Saint John’s wort. Lancet 2000, 355:548–549.PubMedCrossRefGoogle Scholar
  10. 10.
    Piscitelli SC, Burstein AH, Chaitt D, et al.: Indinavir concentrations and St John’s wort. Lancet 2000, 355:547–548.PubMedCrossRefGoogle Scholar
  11. 11.
    Mathijssen RHJ, Verweij J, De Bruijn P, et al.: Modulation of irinotecan (CPT-11) metabolism by St. John’s wort in cancer patients [abstract]. Proc Am Assoc Cancer Res 2002, 43:492.Google Scholar
  12. 12.
    Bonham MJ, Galkin A, Montgomery B, et al.: Effects of the herbal extract PC-SPES on microtubule dynamics and paclitaxel-mediated prostate tumor growth inhibition. J Natl Cancer Inst 2002, 94:1641–1647.PubMedGoogle Scholar
  13. 13.
    Jatoi A, Dakhil S, Burch P, et al.: A phase II trial of green tea for androgen-independent prostate cancer: a North Central Cancer Treatment Group (NCCTG) trial [abstract]. Proc Am Assoc Cancer Res 2002, 43:492.Google Scholar
  14. 14.
    Parker MG: Shark cartilage-induced hepatitis. Ann Intern Med 1996, 125:780–781.Google Scholar
  15. 15.
    Miller DR, Anderson GT, Stark JJ, et al.: Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol 1998, 16:3649–3655.PubMedGoogle Scholar
  16. 16.
    Hainer MI, Tsai N, Komura ST, Chiu CL: Fatal hepatorenal failure associated with hydrazine sulfate. Ann Intern Med 2000, 133:877–880.PubMedGoogle Scholar
  17. 17.
    Moertel CG, Fleming TR, Rubin J, et al.: A clinical trial of amygdalin (laetrile) in the treatment of human cancer. N Engl J Med 1982, 306:201–206.PubMedCrossRefGoogle Scholar
  18. 18.
    Nortier JL, Martinez M-CM, Schmeiser HH, et al.: Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000, 342:1686–1692.PubMedCrossRefGoogle Scholar
  19. 19.
    Lord GM, Cook T, Arlt VM, et al.: Urothelial malignant disease and Chinese herbal nephropathy. Lancet 2001, 358:1515–1516.PubMedCrossRefGoogle Scholar
  20. 20.
    Grossman L: The curious case of kava: Why did it take the FDA so long to finally sound the alarm? Time 2002, April 8, p 58.Google Scholar
  21. 21.
    Ernst E: The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John’s wort, ginseng, echinacea, saw palmetto, and kava. Ann Intern Med 2002, 136:42–53.PubMedGoogle Scholar
  22. 22.
    White J: PC-SPES: a lesson for future dietary supplement research. J Natl Cancer Inst 2002, 94:1261–1262.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Maurie Markman
    • 1
  1. 1.Department of Hematology/Medical OncologyThe Cleveland Clinic FoundationClevelandUSA

Personalised recommendations